| Acquisition AUROPHARMA : Aurobindo Pharma Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on November 12, 2018, has inter alia, transacted the following business: Our wholly owned subsidiary, Aurobindo Pharma USA Inc., USA, has entered into an agreement to acquire a product under development and related assets from �Advent Pharmaceuticals Pty Ltd., Australia, through AuroScience Pty Limited, Melbourne, a 100% subsidiary of Aurobindo Pharma USA Inc., USA. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as �Annexure A�. | 13/Nov/2018 |
